We are working to repurpose our novel monoclonal antibody Itolizumab
(used in psoriasis) to treat complications caused by Covid-19
infection. If we can successfully establish the potential role for our
molecule in treating Covid-19 complications, it will enable us to
address a critical unmet need, Kiran Mazumdar-Shaw said.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/looking-at-repurposing-drugs-biocon/articleshow/75501179.cms
No comments:
Post a Comment